ZA201902868B - Synthetic chimeric poxviruses - Google Patents

Synthetic chimeric poxviruses

Info

Publication number
ZA201902868B
ZA201902868B ZA2019/02868A ZA201902868A ZA201902868B ZA 201902868 B ZA201902868 B ZA 201902868B ZA 2019/02868 A ZA2019/02868 A ZA 2019/02868A ZA 201902868 A ZA201902868 A ZA 201902868A ZA 201902868 B ZA201902868 B ZA 201902868B
Authority
ZA
South Africa
Prior art keywords
synthetic chimeric
chimeric poxviruses
poxviruses
synthetic
chimeric
Prior art date
Application number
ZA2019/02868A
Other languages
English (en)
Inventor
Evans David
Noyce Ryan
Lederman Seth
Original Assignee
Evans David
Noyce Ryan
Lederman Seth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans David, Noyce Ryan, Lederman Seth filed Critical Evans David
Publication of ZA201902868B publication Critical patent/ZA201902868B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2019/02868A 2016-11-02 2019-05-07 Synthetic chimeric poxviruses ZA201902868B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US201662434794P 2016-12-15 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Publications (1)

Publication Number Publication Date
ZA201902868B true ZA201902868B (en) 2022-12-21

Family

ID=62075555

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA2019/02868A ZA201902868B (en) 2016-11-02 2019-05-07 Synthetic chimeric poxviruses
ZA2022/04981A ZA202204981B (en) 2016-11-02 2022-05-06 Synthetic chimeric poxviruses
ZA2024/03393A ZA202403393B (en) 2016-11-02 2024-05-02 Synthetic chimeric poxviruses

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA2022/04981A ZA202204981B (en) 2016-11-02 2022-05-06 Synthetic chimeric poxviruses
ZA2024/03393A ZA202403393B (en) 2016-11-02 2024-05-02 Synthetic chimeric poxviruses

Country Status (13)

Country Link
US (3) US11345896B2 (https=)
EP (1) EP3535389A4 (https=)
JP (3) JP2019535311A (https=)
CN (1) CN110431228B (https=)
AU (2) AU2017353868C1 (https=)
BR (1) BR112019008781A2 (https=)
CA (1) CA3042694A1 (https=)
IL (2) IL266399B2 (https=)
MX (1) MX2019005102A (https=)
SG (1) SG11201903893PA (https=)
TW (2) TW202528334A (https=)
WO (1) WO2018085582A1 (https=)
ZA (3) ZA201902868B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス, 合成キメラポックスウイルス
US20180228921A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
EP3788142A4 (en) * 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
KR20220165731A (ko) * 2020-02-26 2022-12-15 토닉스 파마 리미티드 Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
JP2024505274A (ja) 2021-02-02 2024-02-05 ゲオバックス インコーポレイテッド ワクチン接種中のt細胞プライミングの強化において使用されるウイルスコンストラクト
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
JPWO2006022215A1 (ja) 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 SARS−コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
WO2014166084A1 (en) 2013-04-10 2014-10-16 Totbiopharm Shanghai R & D Center Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
AU2017332367B2 (en) 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス, 合成キメラポックスウイルス
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CN112261951A (zh) 2018-05-02 2021-01-22 通尼克斯制药控股有限公司 包含合成嵌合痘苗病毒的干细胞及其使用方法
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS

Also Published As

Publication number Publication date
AU2017353868B2 (en) 2024-02-29
MX2019005102A (es) 2019-10-30
US20230002741A1 (en) 2023-01-05
IL266399B1 (en) 2025-05-01
TW202528334A (zh) 2025-07-16
IL319942A (en) 2025-05-01
US11345896B2 (en) 2022-05-31
TW201819400A (zh) 2018-06-01
ZA202204981B (en) 2024-09-25
JP2022164900A (ja) 2022-10-27
IL266399A (en) 2019-06-30
IL266399B2 (en) 2025-09-01
AU2024200997A1 (en) 2024-03-07
EP3535389A1 (en) 2019-09-11
US20180251736A1 (en) 2018-09-06
JP2019535311A (ja) 2019-12-12
TWI887191B (zh) 2025-06-21
AU2017353868A1 (en) 2019-05-16
CN110431228B (zh) 2024-04-02
BR112019008781A2 (pt) 2019-07-16
US12365879B2 (en) 2025-07-22
AU2017353868C1 (en) 2024-06-06
ZA202403393B (en) 2025-08-27
CN110431228A (zh) 2019-11-08
WO2018085582A1 (en) 2018-05-11
US20260022350A1 (en) 2026-01-22
NZ752893A (en) 2025-10-31
SG11201903893PA (en) 2019-05-30
CA3042694A1 (en) 2018-05-11
JP2024107257A (ja) 2024-08-08
EP3535389A4 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
ZA201902868B (en) Synthetic chimeric poxviruses
GB201712093D0 (en) Not known
GB201602934D0 (en) Compounds
GB201605073D0 (en) Brush
GB201620119D0 (en) Compounds
GB201619694D0 (en) Compounds
GB201610854D0 (en) Compounds
GB201604020D0 (en) Compounds
GB201604027D0 (en) Compounds
SI3464336T1 (sl) Spojine
IL263228A (en) Benzoxaborole compounds
GB201505306D0 (en) Chimeric polypeptides
GB201613946D0 (en) Compounds
GB201608777D0 (en) Compounds
GB201604022D0 (en) Compounds
GB201604030D0 (en) Compounds
ZA201903764B (en) Synthetic lures
ZA201804867B (en) Spool
GB201713217D0 (en) Compounds
GB201621520D0 (en) Compounds
GB201609083D0 (en) Synthetic compound
GB201622362D0 (en) Compounds
GB201604029D0 (en) Compounds
GB201622365D0 (en) Compounds
GB201604031D0 (en) Compounds